Last Updated : May 14, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name Sort ascending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Incivek | Telaprevir | Hepatitis C, chronic | List with clinical criteria and/or conditions | Complete | ||
| Incivek | Telaprevir | Hepatitis C, chronic | List with criteria/condition | Complete | ||
| Incivek | Telaprevir | Hepatitis C, chronic | List with criteria/condition | Complete | ||
| Revestive | teduglutide | Short Bowel Syndrome (SBS), pediatrics | Reimburse with clinical criteria and/or conditions | Complete | ||
| Revestive | Teduglutide | Short bowel syndrome | Reimburse with clinical criteria and/or conditions | Complete | ||
| Sivextro | Tedizolid phosphate | Acute bacterial skin and skin structure infections | Withdrawn | |||
| Tecvayli | teclistamab | Relapsed or refractory multiple myeloma | Reimburse with clinical criteria and/or conditions | Active | ||
| Kimmtrak | tebentafusp | unresectable or metastatic uveal melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Nucynta | tapentadol hydrochloride | pain, severe | Do not reimburse | Complete | ||
| Nucynta CR | Tapentadol | Pain, moderate to moderately severe | Do not list | Complete |
Last Updated : May 14, 2024